Glaxo takes 19 percent of Aspen

Glaxo had originally said it would have a 16 percent holding when the deal was announced in May, but it has since bought additional Aspen shares to increase its interest.

The asset-swap deal expands Glaxo's emerging market presence -- a key objective for chief executive Andrew Witty -- and cements an existing relationship between the two businesses.

Aspen has issued 68.5 million new shares to Glaxo in exchange for Glaxo's manufacturing plant in Bad Oldesloe, Germany, and eight specialist medicines.

Taken together with Aspen shares bought by Glaxo between signing and closing, this issue takes Glaxo's holding in Aspen to a total of 81.7 million shares, equivalent to 19 percent.

Abbas Hussain, Glaxo's head of emerging markets, will be appointed to Aspen's board as a non-executive director from December 7.

(Reporting by Ben Hirschler; Editing by Dan Lalor)